Cambridge Theranostics Ltd (CTL), a biotech spin-out company from Cambridge University, announced today a major deal that will allow CTL to commercialize a novel pharmaceutical product that should provide substantial benefits and health improvements in patients with coronary heart disease. CTL intends to obtain rapid regulatory approval for this pharmaceutical product with a view to launching it as soon as possible.
